Want to see IN:ASTEC full AI Analyst Report?
ASTEC Stock Chart & Stats
₹703.50
-₹43.60(-3.76%)
At close: 4:00 PM EST
₹703.50
-₹43.60(-3.76%)
Day’s Range― - ―
52-Week Range₹512.35 - ₹936.00
Previous CloseN/A
Volume22.45K
Average Volume (3M)412.49K
Market Cap
₹13.20B
Enterprise Value₹16.39K
Total Cash (Recent Filing)₹100.49M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-30.27
Shares Outstanding22,282,820
10 Day Avg. Volume47,730
30 Day Avg. Volume412,490
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)2.96
Price to Sales (P/S)2.58
P/FCF Ratio-9.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-15.1
Revenue Forecast (FY)₹5.64B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe FY26 revenue rebound indicates improving demand or volumes after two weaker years. Sustained top-line recovery could improve operating leverage and provide a foundation for restoring profitability, although this remains unproven.
Agrochemical Manufacturing BaseAstec operates in essential crop-protection inputs and supplies technical products to domestic and international customers. Its manufacturing capabilities and exposure to multiple agrochemical categories provide a durable platform for customer retention and demand.
Substantial Equity And Asset BaseA substantial equity and asset base provides some operating capacity and financial cushion while management addresses losses and cash burn. This support may help preserve business continuity, though it does not remove the risks from elevated leverage.
Bears Say
Sustained LossesThe shift to large losses across three consecutive fiscal years indicates that the business model is not currently converting revenue into sustainable earnings. Persistent negative operating profit can weaken reinvestment capacity and increase dependence on external funding.
Elevated LeverageThe sharp increase in debt relative to equity reduces financial flexibility and raises refinancing and interest-burden risk. If weak earnings persist, leverage could constrain investment, pressure liquidity, and make recovery more dependent on balance-sheet support.
Negative Cash GenerationPersistent free-cash-flow deficits show that operations have not been self-funding, while the FY26 operating cash outflow marks a significant deterioration. Continued cash burn could require financing and limit the company’s ability to fund growth internally.
Astec Lifesciences Limited News
ASTEC FAQ
What was Astec Lifesciences Limited’s price range in the past 12 months?
Astec Lifesciences Limited lowest stock price was ₹512.35 and its highest was ₹936.00 in the past 12 months.
What is Astec Lifesciences Limited’s market cap?
Astec Lifesciences Limited’s market cap is ₹13.20B.
When is Astec Lifesciences Limited’s upcoming earnings report date?
Astec Lifesciences Limited’s upcoming earnings report date is Oct 23, 2026 which is in 56 days.
How were Astec Lifesciences Limited’s earnings last quarter?
Astec Lifesciences Limited released its earnings results on Jul 31, 2026. The company reported -₹8.4 earnings per share for the quarter, beating the consensus estimate of -₹8.85 by ₹0.45.
Is Astec Lifesciences Limited overvalued?
According to Wall Street analysts Astec Lifesciences Limited’s price is currently Overvalued.
Does Astec Lifesciences Limited pay dividends?
Astec Lifesciences Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of N/A. See more information on Astec Lifesciences Limited dividends here
What is Astec Lifesciences Limited’s EPS estimate?
Astec Lifesciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Astec Lifesciences Limited have?
Astec Lifesciences Limited has 22,282,820 shares outstanding.
What happened to Astec Lifesciences Limited’s price movement after its last earnings report?
Astec Lifesciences Limited reported an EPS of -₹8.4 in its last earnings report, beating expectations of -₹8.85. Following the earnings report the stock price went up 4.643%.
Which hedge fund is a major shareholder of Astec Lifesciences Limited?
Currently, no hedge funds are holding shares in IN:ASTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astec Lifesciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservative. It also provides herbicides, insecticides, and specialty chemical products. The company also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.
Technical Analysis
Bharat Rasayan Limited
―
Dhanuka Agritech Limited
―
Insecticides (India) Limited
―
India Pesticides Ltd.
―
Sharda Cropchem Ltd.
―